Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.49 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 3/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | CASP9 | P55211 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21739937 | 0.85 | AHR (0.46) | AHRSMYD3LRRK2PDK2GRM5 | |
| SCHEMBL2611032 | 0.82 | AHR (0.56) | AHRSMYD3PDK2GRM5TDP2 | |
| SCHEMBL20133675 | 0.77 | AHR (0.50) | AHRSMYD3LRRK2PDK2GRM5 | |
| SCHEMBL2078454 | 0.76 | AHR (0.56) | AHRSMYD3PDK2GRM5TDP2 | |
| SCHEMBL10650600 | 0.72 | AHR (0.51) | AHRSMYD3LRRK2PDK2GRM5 | |
| Hydrochloric Acid SCHEMBL32664892 | 0.71 | AHR (0.48) | AHRSMYD3LRRK2PDK2GRM5 | |
| SCHEMBL21739972 | 0.71 | SMYD3 (0.36) | AHRSMYD3LRRK2GRM5BRD4 | |
| SCHEMBL10648269 | 0.71 | AHR (0.46) | AHRSMYD3LRRK2PDK2GRM5 | |
| SCHEMBL433799 | 0.70 | AHR (0.61) | AHRSMYD3PDK2GRM5TDP2 | |
| SCHEMBL32690558 | 0.69 | AHR (0.42) | AHRSMYD3GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | AHR 3225/4885SMYD3 489/4885LRRK2 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.